DM
RNAM

Deerfield Management’s Avidity Biosciences RNAM Stock Holding History

Deerfield Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-18,708
Closed -$169K – 424
2023
Q4 		$169K Buy
+18,708
New +$125K ﹤0.01% 186
2021
Q3 		– Sell
-560,132
Closed -$13.8M – 151
2021
Q2 		$13.8M Buy
560,132
+106,159
+23% +$2.47M 0.25% 97
2021
Q1 		$9.9M Hold
453,973
– – 0.21% 104
2020
Q4 		$11.6M Sell
453,973
-20,213
-4% -$589K 0.23% 95
2020
Q3 		$13.3M Sell
474,186
-402,825
-46% -$11.6M 0.33% 75
2020
Q2 		$24.8M Buy
+877,011
New +$25.3M 0.72% 44

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deerfield Management's RNAM Position: Q1 2024 in Review

Deerfield Management sold out of Avidity Biosciences (RNAM) in Q1 2024, closing a stake of 18,708 shares — an estimated $169K sold.

Deerfield Management first reported a position in RNAM in Q2 2020 and held it in 6 quarters. The position peaked at $24.8M in Q2 2020. 158 funds tracked by Wall St. Rank hold RNAM as of Q1 2024.

  • Deerfield Management reported no remaining Avidity Biosciences position as of Q1 2024 after selling out during the quarter.
  • Deerfield Management sold 18,708 Avidity Biosciences shares in Q1 2024, an estimated $169K.
  • Deerfield Management first reported a position in Avidity Biosciences in Q2 2020 and held it in 6 quarters.
  • Deerfield Management's Avidity Biosciences position peaked at $24.8M in Q2 2020.
  • 158 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2024.

Based on Deerfield Management's 13F filing for Q1 2024, filed 15 May 2024.